Brief: Vaxcyte Advances To Second Stage Of Ongoing Phase 2 Study Evaluating VAX-24 For Prevention Of Invasive Pneumococcal Disease In Infants
11/07/2023 14:10
July 11 (Reuters) - Vaxcyte Inc PCVX.O :
* VAXCYTE ADVANCES TO SECOND STAGE OF ONGOING PHASE 2 STUDY
EVALUATING VAX-24 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL
DISEASE IN INFANTS
* VAXCYTE INC - INITIATION OF STAGE 2 APPROVED BY
INDEPENDENT DATA
SAFETY MONITORING BOARD FOLLOWING REVIEW OF STAGE 1 SAFETY AND
TOLERABILITY DATA
* VAXCYTE- EXPECTS TO ANNOUNCE TOPLINE DATA FROM PRIMARY
IMMUNIZATION SERIES BY 2025, FOLLOWED BY TOPLINE DATA FROM
BOOSTER DOSE ABOUT 9 MONTHS LATER
Source text for Eikon: ID:nGNXbKynn0
Further company coverage: PCVX.O
((reuters.briefs@thomsonreuters.com;))